Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 5, 2019
Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate...
-
Nov 1, 2019
Boston Scientific Corporation (NYSE: BSX) will participate in four conferences, including one industry conference and three investor conferences, this month. On November 5, 2019, Jeff Mirviss,...
-
Oct 23, 2019
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.707 billion during the third quarter of 2019. This represents growth of 13.1 percent on a reported basis, 14.2 percent on an...
-
Oct 22, 2019
Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced the commencement of a cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount (the...
-
Oct 1, 2019
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2019 on Wednesday, October...
-
Sep 26, 2019Study of abbreviated antiplatelet therapy for patients at high risk for bleeding after undergoing percutaneous coronary intervention
Boston Scientific (NYSE: BSX) has announced primary endpoint results from the EVOLVE Short DAPT clinical trial, the first prospective study initiated in the U.S. to examine the safety of a...
-
Sep 18, 2019
Boston Scientific Corporation (NYSE: BSX) today announced key data that will be presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the...
-
Aug 20, 2019
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2019 Wells Fargo Securities Healthcare Conference on Thursday, September 5, 2019 in Boston. Mike Mahoney, chairman and...
Aug 19, 2019Boston Scientific Corporation (NYSE:BSX) announced the U.S. Food and Drug Administration (FDA) approval of its ImageReady™ MRI labeling for the Vercise Gevia™ Deep Brain Stimulation (DBS)...
-
Aug 19, 2019
Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. (LSE: BTG) pursuant to the previously announced scheme of arrangement. BTG develops and...
-
Aug 7, 2019
On August 7, 2019, the U.S. Food and Drug Administration (FDA) published guidance to physicians about the benefit-risk profile of peripheral paclitaxel devices intended for the treatment of...
-
Jul 25, 2019
Boston Scientific Corporation (NYSE: BSX) will participate in the 39th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019 in Boston. Susie Lisa, vice president, Investor...
-
Jul 24, 2019
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.631 billion during the second quarter of 2019. This represents growth of 5.6 percent on a reported basis, 8.0 percent on an...
-
Jul 1, 2019
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2019 on Wednesday, July 24,...
-
Jun 26, 2019Momentum across business units and regions targeted to deliver top tier revenue growth and double-digit adjusted earnings per share growth with strong adjusted free cash flow
Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to review its business and long-term growth strategies. The company is...
-
Jun 20, 2019
We appreciate the perspectives shared about the safety and benefits of peripheral paclitaxel devices during the FDA’s meeting of the Circulatory System Devices Panel. Boston Scientific shares...
-
Jun 19, 2019
On June 19-20, 2019, the U.S. Food and Drug Administration (FDA) held a meeting of the Circulatory System Devices Panel about peripheral devices with paclitaxel. Although data on the Boston...
-
Jun 11, 2019
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Vertiflex, Inc., a privately-held company that developed and commercialized the Superion® Indirect...
-
May 22, 2019Findings could expand number of patients who can receive alternative treatment to life-long use of blood thinners
Boston Scientific Corporation (NYSE: BSX) has initiated the OPTION trial to compare safety and effectiveness of the next-generation WATCHMAN FLX™ left atrial appendage closure (LAAC) platform to...
-
May 15, 2019
Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 35th Annual Strategic Decisions Conference on Wednesday, May 29, 2019 in New York City. Mike Mahoney, chairman and chief...
-
May 10, 2019New data further support use of S-ICD System as first-line therapy for majority of ICD patients
Boston Scientific (NYSE: BSX) today announced acute results from the UNTOUCHED study evaluating safety and efficacy of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System for...
-
May 9, 2019Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies
Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Vertiflex, Inc., a privately-held company which has developed and commercialized the...
-
May 7, 2019
Boston Scientific Corporation (NYSE: BSX) will participate in the 2019 UBS Global Healthcare Conference on Tuesday, May 21, 2019 in New York City. Art Butcher, senior vice president and president,...
-
May 6, 2019New Stent System Now Available for Treating Patients with Deep Venous Blockages
Boston Scientific (NYSE: BSX) announced today that the U.S Food and Drug Administration (FDA) has approved the VICI VENOUS STENT™ System for the treatment of iliofemoral venous obstructive...
-
May 1, 2019
Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Heart Rhythm Scientific Sessions, in San...